SURVYR

ALVO

Alvotech
$5.13
+$0.01 (0.20%)Oct 21 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-66%-45%-24%-3%+17%Oct 2025Oct 2026Apr 202652w high $8.5052w low $2.94
ALVOSPY
Wall St. Highest PT $9.00 (+75.4%) Wall St. Avg PT $7.20 (+40.4%)
$3$5$6$8$10POC $5Hi $9Avg $7
Underwater Drawdown %Max DD -65.1%Current -40.3%
0.0%-65.1%
Relative Strength vs SPY-56.7% vs SPYUnderperforming
+91%0%-91%
1W
−$0.04 (0.77%)
1M
−$0.75 (12.76%)
3M
+$1.94 (60.82%)
6M
+$1.63 (46.57%)
YTD
+$0.00 (0.00%)
1Y
−$3.39 (39.79%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
5 analysts · mean score 1.57
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$5.13
Average target$7.20
+$2.07 (+40.4%) upsideaverage target vs current price
CurrentAverageMedian
Low$4.00
Median$7.20
High$9.00
12-month Wall Street target range
Recent analyst rating changes · 23
Upgrade
2026-09-16 · Barclays upgraded ALVO from Underweight to Overweight
Initiated
2026-08-24 · B of A Securities started covering ALVO at Buy
Initiated
2026-08-14 · Evercore ISI Group started covering ALVO at Outperform
Reiterated
2026-03-24 · UBS reiterated Buy on ALVO
Reiterated
2026-03-24 · Barclays reiterated Underweight on ALVO
Initiated
2025-12-09 · Barclays started covering ALVO at Underweight
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$1.7B
P/E (next 12 months, estimated)20.8
52-week range$2.94 – $8.50
Revenue growth (latest quarter vs a year ago)-38.9%
Dividend yieldNo dividend
Analyst consensusBuy (5)
Average analyst price target$7.20 (+40%)

What they do

Alvotech develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions.

Healthcare · Drug Manufacturers - Specialty & Generic
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for ALVO yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

ALVO earningsNext report in 14 days
Next report · quarter Sep 2026
Wed Nov 11, 2026Time not confirmed
EPS consensus-$0.05 range -$0.07–-$0.02
Revenue consensus$138.1M 1 analysts
Last 4 quarters · EPS vs estimate
Aug 19, 2026-$0.11est -$0.08−30.2%Below estimates
May 5, 2026-$0.09est -$0.07−28.6%Below estimates
Mar 17, 2026$0.01est -$0.01+190.8%Above estimates
Nov 12, 2025-$0.11est -$0.03−230.9%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-22 23:32:06 ET
24-0824-1125-0325-0825-1126-0326-0526-08-0.480.18
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$105.8M-38.9%
2026-03-31$105.9M–
2025-12-31$166.6M–
2025-09-30$113.7M–
2025-06-30$173.2M–

News & catalysts

More news
New Strong Sell Stocks for October 21st
Zacks · Oct 21
New Strong Sell Stocks for October 20th
Zacks · Oct 21
Alvotech's Manufacturing Progress, Simponi Launch Potential Support Recovery, UBS Says
MT Newswires · Oct 20
Sector Update: Healthcare Stocks Flat to Higher Premarket Tuesday
MT Newswires · Oct 20
Alvotech Says FDA Approves New Manufacturing Process for Simlandi; Shares Rise Pre-Bell
MT Newswires · Oct 20
Rating changes
Upgrade
2026-09-16 · Barclays upgraded ALVO from Underweight to Overweight
Initiated
2026-08-24 · B of A Securities started covering ALVO at Buy
Initiated
2026-08-14 · Evercore ISI Group started covering ALVO at Outperform
Reiterated
2026-03-24 · UBS reiterated Buy on ALVO
Reiterated
2026-03-24 · Barclays reiterated Underweight on ALVO
Initiated
2025-12-09 · Barclays started covering ALVO at Underweight

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-22 23:32:06 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026